The global hemophilia drugs market size was estimated to be USD 12.76 billion in 2023 and is expected to reach at USD 28.37 billion by 2034 with a CAGR of 7.53% during the forecast period 2024-2034. High prevalence of hemophilia, rising awareness regarding hemophilia disorders, growing government support initiatives for early detection in neonates, increasing investment in research & development activities, surge in approvals of gene therapies for hemophilia treatment, and rising focus on development of innovative treatment for hemophilia are some of the key factors boosting the market growth.
Rising focus on development of innovative treatment for hemophilia is predicted to boost the market growth during the forecast period. Individuals afflicted by hemophilia typically experience unusual and prolonged bleeding episodes, primarily due to the genetic anomaly in the hemophilia gene, which retards the blood clotting mechanism. Consequently, industry stakeholders are directing their efforts towards the advancement of more sophisticated hemophilia treatment alternatives. For instance, in March 2022, Freeline Therapeutics Holdings plc administered the initial dose to a patient in the Phase 1/2 B-LIEVE clinical trial, which aims to confirm the appropriate dosage of FLT180a for treating hemophilia B. Hemophilia B is a genetic bleeding disorder that results from a deficiency of clotting factor IX protein.
By type, hemophilia A was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to increasing prevalence of hemophilia A, rising supportive government initiatives to launch products, growing advancements in recombinant protein engineering, surge in introduction of gene therapy, and increasing research on gene therapies for Hemophilia A. For instance, in June 2022, The FDA has awarded Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) as a treatment for individuals with hemophilia A, a rare and life-threatening bleeding condition, based on pivotal data from the Phase 3 XTEND-1 study. Sanofi and Sobi have partnered to jointly develop and market efanesoctocog alfa. Additionally, hemophilia B is predicted to grow at fastest CAGR during the forecast period owing to the increasing launching of gene therapy and growing demand for advanced products for the treatment of hemophilia.
By treatment, prophylaxis was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to rising utilization of the bi-specific antibody product Helimbra (emicizumab) to treat the deficiency of clotting factor FVIII and growing regulatory approvals by regulatory bodies. For instance, in June 2023, The first patient in the United States has received hemophilia B treatment using the FDA-approved HEMGENIX® (etranacogene dezaparvovec-drlb), according to CSL Behring, a well-known international biotechnology business. Additionally, cure is predicted to grow at fastest CAGR during the forecast period owing to the growing approvals of multiple gene therapy by regulatory bodies and rising launch of innovative therapies.
By therapy, factor replacement therapy was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to rising focus on development of advanced therapies and increasing approvals of novel therapies by regulatory bodies. For instance, in February 2023, Sanofi's weekly Factor VIII replacement therapy ALTUVIIIO has gained approval from the U.S. FDA for both on-demand and preventive treatment of hemophilia A. Additionally, gene therapy & monoclonal antibodies is predicted to grow at fastest CAGR during the forecast period owing to the rising research & development activities and surge in introduction of innovative gene therapies by major market players.
By end-user, specialty clinics was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to surge in number of trained professionals that can offer hemophilia treatment and rising research & development activities for the development of novel therapies. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of hemophilia and increasing approval of gene therapy by regulatory authorities. For instance, in February 2023, CSL Behring has received conditional authorization from the European Commission for its gene therapy Hemgenix to address hemophilia B. This product has already been sanctioned in the United States and is accessible for a single treatment at a cost of USD 3.5 million.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in therapeutic advancements in hemophilia, increasing prevalence of hemophilia, growing awareness regarding technologically advanced products, and rising approvals by Food and Drug Administration (FDA). For instance, in June 2023, BioMarin Pharmaceutical Inc. disclosed that the U.S. Food and Drug Administration (FDA) has given its approval to ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for addressing severe hemophilia A in adult patients. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of hemophilia, surge in prevalence of hemophilia, rising novel product approvals by regulatory authorities, and growing research & development activities for effective therapies. For instance, In February 2022, The Phase 3 GENEr8-1 experiment was evaluated after two years by BioMarin Pharmaceutical Inc., which also gave a thorough safety update on the valoctocogene roxaparvovec drug. This gene therapy is under investigation for its potential to treat severe hemophilia A in adults. The presentation took place during the 15th Annual Virtual Congress hosted by the European Association for Haemophilia and Allied Disorders (EAHAD).
Rising focus on development of innovative treatment for hemophilia is predicted to boost the market growth during the forecast period. Individuals afflicted by hemophilia typically experience unusual and prolonged bleeding episodes, primarily due to the genetic anomaly in the hemophilia gene, which retards the blood clotting mechanism. Consequently, industry stakeholders are directing their efforts towards the advancement of more sophisticated hemophilia treatment alternatives. For instance, in March 2022, Freeline Therapeutics Holdings plc administered the initial dose to a patient in the Phase 1/2 B-LIEVE clinical trial, which aims to confirm the appropriate dosage of FLT180a for treating hemophilia B. Hemophilia B is a genetic bleeding disorder that results from a deficiency of clotting factor IX protein.
By type, hemophilia A was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to increasing prevalence of hemophilia A, rising supportive government initiatives to launch products, growing advancements in recombinant protein engineering, surge in introduction of gene therapy, and increasing research on gene therapies for Hemophilia A. For instance, in June 2022, The FDA has awarded Breakthrough Therapy designation to efanesoctocog alfa (BIVV001) as a treatment for individuals with hemophilia A, a rare and life-threatening bleeding condition, based on pivotal data from the Phase 3 XTEND-1 study. Sanofi and Sobi have partnered to jointly develop and market efanesoctocog alfa. Additionally, hemophilia B is predicted to grow at fastest CAGR during the forecast period owing to the increasing launching of gene therapy and growing demand for advanced products for the treatment of hemophilia.
By treatment, prophylaxis was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to rising utilization of the bi-specific antibody product Helimbra (emicizumab) to treat the deficiency of clotting factor FVIII and growing regulatory approvals by regulatory bodies. For instance, in June 2023, The first patient in the United States has received hemophilia B treatment using the FDA-approved HEMGENIX® (etranacogene dezaparvovec-drlb), according to CSL Behring, a well-known international biotechnology business. Additionally, cure is predicted to grow at fastest CAGR during the forecast period owing to the growing approvals of multiple gene therapy by regulatory bodies and rising launch of innovative therapies.
By therapy, factor replacement therapy was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to rising focus on development of advanced therapies and increasing approvals of novel therapies by regulatory bodies. For instance, in February 2023, Sanofi's weekly Factor VIII replacement therapy ALTUVIIIO has gained approval from the U.S. FDA for both on-demand and preventive treatment of hemophilia A. Additionally, gene therapy & monoclonal antibodies is predicted to grow at fastest CAGR during the forecast period owing to the rising research & development activities and surge in introduction of innovative gene therapies by major market players.
By end-user, specialty clinics was the highest revenue-grossing segment in the global hemophilia drugs market in 2023 owing to surge in number of trained professionals that can offer hemophilia treatment and rising research & development activities for the development of novel therapies. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of hemophilia and increasing approval of gene therapy by regulatory authorities. For instance, in February 2023, CSL Behring has received conditional authorization from the European Commission for its gene therapy Hemgenix to address hemophilia B. This product has already been sanctioned in the United States and is accessible for a single treatment at a cost of USD 3.5 million.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in therapeutic advancements in hemophilia, increasing prevalence of hemophilia, growing awareness regarding technologically advanced products, and rising approvals by Food and Drug Administration (FDA). For instance, in June 2023, BioMarin Pharmaceutical Inc. disclosed that the U.S. Food and Drug Administration (FDA) has given its approval to ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for addressing severe hemophilia A in adult patients. Additionally, Europe region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of hemophilia, surge in prevalence of hemophilia, rising novel product approvals by regulatory authorities, and growing research & development activities for effective therapies. For instance, In February 2022, The Phase 3 GENEr8-1 experiment was evaluated after two years by BioMarin Pharmaceutical Inc., which also gave a thorough safety update on the valoctocogene roxaparvovec drug. This gene therapy is under investigation for its potential to treat severe hemophilia A in adults. The presentation took place during the 15th Annual Virtual Congress hosted by the European Association for Haemophilia and Allied Disorders (EAHAD).
Segmentation: Hemophilia Drugs Market Report 2022 - 2033
Hemophilia Drugs Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Hemophilia A
- Hemophilia B
- Others
Hemophilia Drugs Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Prophylaxis
- Cure
- On-demand
Hemophilia Drugs Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Gene Therapy & Monoclonal Antibodies
- Desmopressin & Fibrin Sealants
- Factor Replacement Therapy
- Plasma-derived Factor Concentrates
- Factor IX
- Factor VIII
- Recombinant Factor Concentrates
- Factor IX
- Factor VII
- Factor VIII
Hemophilia Drugs Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Specialty Clinics
- Hospitals
Hemophilia Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Hemophilia Drugs Market: Type Estimates & Trend Analysis
8. Hemophilia Drugs Market: Treatment Estimates & Trend Analysis
9. Hemophilia Drugs Market: Therapy Estimates & Trend Analysis
10. Hemophilia Drugs Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Hemophilia Drugs Market
13. Europe Global Hemophilia Drugs Market
14. Asia Pacific Global Hemophilia Drugs Market
15. Latin America Global Hemophilia Drugs Market
16. MEA Global Hemophilia Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Sanofi
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceutical Inc.
- CSL Behring
- Spark Therapeutics Inc.
- Freeline Therapeutics Holdings plc
- Pfizer Inc.
- Bayer AG
- Sangamo Therapeutics Inc.
- F. Hoffmann La-Roche Ltd.
- Octapharma AG
- Novo Nordisk A/S.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 12.76 Billion |
| Forecasted Market Value ( USD | $ 28.37 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
